These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2054231)

  • 21. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
    Paterson AD; Kanis JA; Cameron EC; Douglas DL; Beard DJ; Preston FE; Russell RG
    Br J Haematol; 1983 May; 54(1):121-32. PubMed ID: 6221750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of tumor-induced osteolysis by APD.
    Burckhardt P; Thiébaud D; Perey L; von Fliedner V
    Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of hypercalcemia of tumoral origin with two diphosphonates].
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Schweiz Med Wochenschr; 1980 Nov; 110(48):1822-4. PubMed ID: 6792698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of malignant hypercalcaemia with clodronate.
    Percival RC; Paterson AD; Yates AJ; Beard DJ; Douglas DL; Neal FE; Russell RG; Kanis JA
    Br J Cancer; 1985 May; 51(5):665-9. PubMed ID: 3158326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.
    Bonjour JP; Philippe J; Guelpa G; Bisetti A; Rizzoli R; Jung A; Rosini S; Kanis JA
    Bone; 1988; 9(3):123-30. PubMed ID: 2971382
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia.
    Sawyer N; Newstead C; Drummond A; Cunningham J
    Bone Miner; 1990 May; 9(2):121-8. PubMed ID: 2350615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Bone Miner Res; 1986 Dec; 1(6):555-62. PubMed ID: 3503561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.
    Jung A
    Am J Med; 1982 Feb; 72(2):221-6. PubMed ID: 6460442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parenteral diphosphonates for treating malignant hypercalcemia.
    Jung A; van Ouwenaller C; Chantraine A; Courvoisier B
    Cancer; 1981 Oct; 48(8):1922-5. PubMed ID: 6456809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
    Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
    Bone; 1986; 7(4):247-53. PubMed ID: 3768203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.